Interleukin-13 Activates Distinct Cellular Pathways Leading to Ductular Reaction, Steatosis, and Fibrosis
Open accessAbstract
Fibroproliferative diseases are driven by dysregulated tissue repair responses and are a major cause of morbidity and mortality because they affect nearly every organ system. Type 2 cytokine responses are critically involved in tissue repair; however, the mechanisms that regulate beneficial regeneration versus pathological fibrosis are not well understood. Here, we have shown that the type 2 effector cytokine interleukin-13 simultaneously, yet independently, directed hepatic fibrosis and the compensatory proliferation of hepatocytes and biliary cells in progressive models of liver disease induced by interleukin-13 overexpression or after infection with Schistosoma mansoni. Using transgenic mice with interleukin-13 signaling genetically disrupted in hepatocytes, cholangiocytes, or resident tissue fibroblasts, we have revealed direct and distinct roles for interleukin-13 in fibrosis, steatosis, cholestasis, and ductular reaction. Together, these studies show that these mechanisms are simultaneously controlled but distinctly regulated by interleukin-13 signaling. Thus, it may be possible to promote interleukin-13-dependent hepatobiliary expansion without generating pathological fibrosis. VIDEO ABSTRACT.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is substantial cross-regulation between IL-17A and IL-13, with marked upregulation of the opposing pathway when only one mechanism is targeted therapeutically.
“several studies have revealed substantial cross-regulation between IL-17A and IL-13110,143, with marked upregulation of the opposing pathway when only one mechanism was targeted therapeutically136,142,144,145”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 55 · Cited by 132
Research works printed but not linked: 1
- Clouston AD Powell EE Walsh MJ Richardson MM Demetris AJ Jonsson JR Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis Hepatology (Baltimore, Md) 2005 41 809 818 15793848
- Authors
- Gieseck, R. L., Ramalingam, T. R., Hart, K. M., Vannella, K. M., Cantu, D. A., Lu, W.-Y., Ferreira-González, S., Forbes, S. J., Vallier, L., & Wynn, T. A.
- Affiliations
- National Institutes of Health (US)
- MRC Centre for Regenerative Medicine (GB)
- Wellcome/MRC Cambridge Stem Cell Institute (GB)
- Corresponding author
- Wynn, Thomas A.
- ORCID
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 45
- Issue
- 1
- Pages
- 145-158
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC4956513
- OpenAlex
- W2472778407
- Cited by
- 132
- References
- 55
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 10 · 2023: 24 · 2022: 12 · 2021: 11 · 2020: 16 · 2019: 14 · 2018: 9 · 2017: 6 · 2016: 4
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by-nc-nd)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institute for Health and Care Research
- National Institutes of Health
- Medical Research Council (MC_PC_12009, MR/K017047/1, MR/K026666/1)
- National Institute of Allergy and Infectious Diseases (Z01AI001019, Z01AI000829)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Keywords
- IL-13, liver fibrosis, ductular reaction, hepatic steatosis, cholestasis, hepatocyte proliferation, cholangiocyte proliferation, Schistosoma mansoni, type 2 cytokines, tissue repair, fibroproliferative disorders, transgenic mice
- MeSH terms
- Animals, Bile Acids and Salts, Cells, Cultured, Fatty Liver, Fibroblasts, Fibrosis, Humans, Liver, Liver Cirrhosis, Biliary, Mice, Inbred C57BL, Schistosoma mansoni, Schistosomiasis mansoni, Signal Transduction, Mice, Knockout, Th2 Cells, Interleukin-13, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review